Abiraterone Acetate 250mg Tablets

Abiraterone Acetate 250mg Tablets is a highly specialized selective inhibitor of the enzyme CYP17 (17α-hydroxylase/C17,20-lyase). This medication is designed to treat advanced prostate cancer by cutting off the production of androgens (testosterone) from all three known sources: the testes, the adrenal glands, and the tumor itself. While traditional hormone therapies (like LHRH agonists) only stop production in the testes, prostate cancer cells can often adapt by producing their own fuel or sourcing it from the adrenals. By irreversibly inhibiting the CYP17 enzyme complex, this drug halts the conversion of pregnenolone and progesterone into testosterone precursors (DHEA and androstenedione). This total androgen blockade deprives the prostate cancer cells of the hormones they need to survive and replicate. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for castration-resistant prostate cancer, offering a powerful mechanism to extend life when standard hormonal treatments no longer suffice.

The 250mg tablet is the foundational dosage unit for the standard adult regimen, which typically requires 1,000mg (four tablets) taken once daily. A critical pharmacokinetic rule for this medication is that it must be taken on an empty stomach. Ingesting the tablets with food can cause a massive increase in systemic absorption—up to 10-fold—which significantly increases the risk of severe side effects. To ensure safety and efficacy, patients must not eat for at least 2 hours before and at least 1 hour after the dose. The 250mg strength allows for precise dose adjustments if a patient develops liver toxicity or other adverse reactions.

Indications and Uses of Abiraterone Acetate 250mg Tablets

Abiraterone Acetate 250mg Tablets is commonly prescribed for the specialized management of the following conditions:

• Metastatic Castration-Resistant Prostate Cancer (mCRPC): It is indicated in combination with prednisone for the treatment of patients with metastatic prostate cancer that has progressed despite surgical or medical castration.
• Metastatic High-Risk Castration-Sensitive Prostate Cancer (mHSPC): The medication is also utilized in combination with prednisone for patients with newly diagnosed metastatic prostate cancer who are still responding to traditional hormone therapy but are at high risk for rapid progression.

Key Features of Abiraterone Acetate 250mg Tablets

• Triple Source Androgen Blockade: The primary feature of Abiraterone Acetate 250mg Tablets is its ability to suppress testosterone production in the testes, adrenals, and the tumor microenvironment simultaneously.
• CYP17 Inhibition: It targets the specific enzyme required for androgen biosynthesis, providing a more comprehensive hormonal control than older therapies.
• Survival Advantage: Clinical trials have demonstrated that adding this medication to standard care significantly improves overall survival and delays the progression of bone pain.
• Oral Treatment: The once-daily oral administration via 250mg tablets provides a convenient at-home alternative to injectable chemotherapies.
• Synergy with Prednisone: It is designed to be used with low-dose corticosteroids to manage the metabolic shifts caused by enzyme inhibition.

Storage for Abiraterone Acetate 250mg Tablets

To preserve the pharmacological stability and ultimate potency of the active ingredients, Abiraterone Acetate 250mg Tablets should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). It is vital to keep the tablets in their original container with the lid tightly closed to protect them from moisture. For maximum safety, always store Abiraterone Acetate 250mg Tablets in a secure, high location that is strictly out of the reach and sight of children and pets.

Safety Warnings for Abiraterone Acetate 250mg Tablets

The administration of Abiraterone Acetate 250mg Tablets must always be accompanied by low-dose Prednisone. Because the drug inhibits CYP17, it causes a decrease in cortisol and an increase in mineralocorticoids. This can lead to severe Hypertension, Hypokalemia (low potassium), and Fluid Retention. Prednisone acts as a replacement for the lost cortisol and prevents these cardiovascular side effects.

Hepatotoxicity: Severe liver damage can occur. Liver function tests (ALT, AST, and bilirubin) must be monitored before starting, every two weeks for the first three months, and monthly thereafter. Cardiac Events: Patients with a history of heart disease should be monitored closely, as the drug can increase the strain on the heart due to fluid shifts.

Adrenal Insufficiency: If patients stop their prednisone or experience severe stress (infection/surgery), they may experience an adrenal crisis. Abiraterone Acetate 250mg Tablets is not indicated for use in women and can cause fetal harm. By strictly following these professional guidelines, including empty-stomach dosing and mandatory prednisone co-administration, healthcare providers can safely maximize the therapeutic benefits of Abiraterone Acetate 250mg Tablets.